First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

Recruiting

Phase 1

Phase 2

ALN-SODFirst in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT06351592

Conditions

Amyotrophic Lateral Sclerosis (ALS)

Mutation in the Superoxide Dismutase-1 (SOD1) Gene

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

ALN-SOD

Diluent

Placebo (PB)

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-05-04. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2026-02-27.